Slide 1: Investor Presentation December 2024
Translated from Polish to English - www.onlinedoctranslator.com PRESENTATION INVESTOR December 2024 The company is listed on Warsaw Stock Exchange
Slide 2: Legal disclaimers
Legal disclaimers This document has been prepared for informational purposes only, contains only summary information and is not intended to be exhaustive, nor is it intended to be the sole basis for any analysis or evaluation. Genomtec SA makes no representations (express or implied) regarding the i
Slide 3: An international team, a combination of science and business
An international team, a combination of science and business MANAGEMENT Miron Tokarsky international team of 20 experts Chairman of the Management Board, Co-founder of the Company two locations: Wrocław and Kent (UK) Co-creator of Genomtec technology and patents Doctor of Medical Sciences in the fie
Slide 4: Technology
GENOMTEC = Technology
Slide 5: Genomtec SNAAT
Genomtec SNAAT Delivering innovative diagnostic technologies close to the patient – Point of Care TEST SCOPE TESTING LOCATION Infections Clinics Epidemiology Doctor's offices Environmental testing Emergency Department Patient transportation Airports SNAAT technology Genomtec is a MedTech company spe
Slide 6: What makes LAMP isothermal technology unique?
What makes LAMP isothermal technology unique? PCR LAMP Requires temperature cycling Isothermal – one constant temperature Requires 2 starters Requires 6 starters Free: usually over 1 hour Fast: usually <30 min Requires a separate reverse transcription step Reverse transcription occurs together with
Slide 7: Genomtec oncoSNAAT
oncoSNAAT Suspicion Therapeutic decision cancer Analytical phase Current standard Preparation Biopsy Insulation Analysis Biopsy order Transport libraries to Sequencing Test result available cancer DNA/RNA bioinformatics sequencing for a doctor – application targeted therapy 48-72 hrs A few to a doze
Slide 8: The effects of using isothermal technologies
The effects of using isothermal technologies SPEED AND HIGH MOBILITY VERSATILITY LOW COST PRECISION ▪ High accuracy ▪ Small analyzer dimensions ▪ Identification of pathogens results and compact card such as viruses and ▪ Simplified construction ▪ Carrying out multiple microfluidic bacteria. microflu
Slide 9: Organizational change of structure
Change of structure organizational
Slide 10: Changes in the organizational structure of the company in connection with the M&A process
Changes in the organizational structure of the company in connection with the M&A process CURRENTLY: GENOMTEC SA. • Adjustment down needs One company carries out all projects buyers • Accelerate M&A transactions • Increase in transaction value AFTER CHANGE: GENOMTEC SA. Parent company 100% 100% 100%
Slide 11: Current operational activities
Current activities operational
Slide 12: M&A process status – synergy of business and R&D activities
M&A process status – synergy of business and R&D activities Several dozen meetings July 2023 - Present Building a list of interested parties Signing of contracts NDA Signing of confidentiality agreements with a number of interested entities. 5 areas interests Exchange of data regarding technologies
Slide 13: The state of the M&A process – technology
The state of the M&A process – technology Environmental requirements and stability of use of the Genomtec ID platform (including temperature, humidity) • A series of tests and optimizations of algorithms controlling the non-contact heating system were carried out in an extended range of outside temp
Slide 14: The state of the M&A process – technology
The state of the M&A process – technology Possibilities of accelerating diagnostics using Genomtec ID. • In conjunction with the work focused on reducing the cost of producing the reaction card, at the request of one of the potential partners, the possibilities of using new reagents to shorten the t
Slide 15: Status of the M&A process – reduction of production costs
Status of the M&A process – reduction of production costs Costs of producing large-scale reaction cards. • Discussions were held with a number of partners specializing in the production of lab-on-chip microfluidic systems. • Two independent quotes (CDMO partners) were obtained related to scaling up
Slide 16: Development of the Onco SNAAT project
Development of the Onco SNAAT project 500+ Conducted laboratory reactions Development of an original method for diagnosing single- nucleotide changes cftDNA Selection of sample volume parameters. Start of work on DNA isolation method. IP Actions aimed at obtaining and extending intellectual property
Slide 17: Market Potential – food safety
Market Potential food safety
Slide 18: The State of the Microbiological Diagnostics Market
The State of the Microbiological Diagnostics Market • Pathogens such asSalmonella, Listeria monocytogenes and E. colipose a significant threat to food safety. In recent years, there has been an increase in the number of cases of Salmonella, E. coli and Listeria in food products. • Millions of cases
Slide 19: The State of the Microbiological Diagnostics Market
The State of the Microbiological Diagnostics Market • Reports of contamination of Polish products constitute 13 percent of cases worldwide. • In addition, the European Commission Audit showed that Sanitary Inspection inspectors did not have sufficient knowledge about taking swab samples to detect th
Slide 20: Diagnostic methods
Diagnostic methods Microbiological cultures waiting time from 48h to >21 days Rapid diagnostic tests low sensitivity and specificity complicated diagnostic process Genetic identification long waiting time >14 days, high cost of analysis Very often it is necessary to conduct pre-cultivation 20
Slide 21: Diagnostic methods
Diagnostic methods Salmonella •Standard:PN-EN ISO 6579-1:2017-04 •Methodology:multi-step detection process, including biochemical and serological confirmations •Duration:up to 7 days •Modern solutions:molecular methods (Real Time-PCR, LAMP) allowing to shorten the diagnostic time E. coli •Reference
Slide 22: Diagnostic methods
Diagnostic methods Limit Time to obtain Test Type Sensitivity (%) Specificity (%) detection (CFU/g Cost (USD) result or ml) PCR (reaction chain 95-99 98-100 1-10 CFU/g 1-4 hours 15-50 polymerases) ELISA-test 85-90 90-95 10^3-10^4 CFU/g 2-6 hours 5-20 Tests Immunochrome 80-85 85-90 10^4-10^5 CFU/g 10
Slide 23: Market forecasts
Market forecasts Market value:By 2030, the pathogen diagnostics market will grow to9 USD billion. Quick tests(mainly antigenic) will increase from USD 3 billion (2021) to USD 5.8 billion (2030). Growth of the molecular methods market:9% per annum. 23
Slide 24: Q&A session
GENOMTEC = Q&A session
Slide 25: investors@genomtec.com genomtec.com
investors@genomtec.com genomtec.com
Slide 26: Genomtec ID: fast, cheap, portable, 5-pathogen test
Genomtec ID: fast, cheap, portable, 5-pathogen test ❖ Genomtec ID –passive reaction card and simple design - a source of competitive advantage Cepheid, Visby Medical Binx Bosch Lucira Health Gene Expert Vivalytic Estimated price Average price Average price Average price Average price Average price €
Slide 27: M&A Process
M&A Process Technology parameters sought by potential acquirers: Clairfield Partners – M&A Advisor Competitive Confirmed has extensive experience in M&A transactions, including in the area of medical technology action technology and biotechnology, including the genetic diagnostics sector. Objective: